Human B-cell receptor (BCR) recognizing HIV-1 envelope (Env) epitopes (HIV-1 Env-specific BCR)

The Human B-cell receptor (BCR) recognizing HIV-1 envelope (Env) epitopes is a critical target in the development of preventative HIV vaccines. This receptor is a membrane-bound immunoglobulin found on the surface of B lymphocytes that mediates the recognition of the HIV-1 spike protein, the only viral protein exposed on the virion surface (Ward & Wilson, 2017). The AMC011 SOSIP is a specific, stabilized trimeric immunogen derived from a Clade B HIV-1 founder virus, designed to present native-like epitopes to these BCRs (Nijhuis et al., 2021). By binding to the BCR, the AMC011 SOSIP trimer initiates a cascade of immune events, including B-cell activation, proliferation, and somatic hypermutation within germinal centers. This process is intended to guide the immune system toward producing broadly neutralizing antibodies (bnAbs) that can recognize conserved regions of the HIV-1 Env across different viral strains (Sanders & Moore, 2017). Targeting these specific BCRs is a cornerstone of modern structure-based vaccine design, which seeks to overcome the high diversity and glycan shielding of the HIV-1 virus. Successful engagement of these receptors is monitored through the induction of high-affinity antibodies and the expansion of antigen-specific memory B-cell populations.

Other names

HIV-1 envelope-specific B-cell receptorAnti-HIV-1 BCRAMC011-binding B-cell receptorHIV-1 Env-specific surface immunoglobulin

The immunogen (e.g., AMC011 SOSIP) acts as a BCR agonist, binding to the surface immunoglobulin and inducing receptor aggregation, which triggers downstream signaling (e.g., via Syk and PLCγ2) leading to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells or memory B cells (Nijhuis et al., 2021; Sanders & Moore, 2017).